What are CanSino Biologics Inc.'s marketed drugs?

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Top marketed products include MCV4, Placebo for Inhalation, TT.

CanSino Biologics Inc.

3 marketed · 8 in Phase 3

Quick facts

Founded	2009

Marketed products

MCV4 · Immunology / Infectious Disease
MCV4 is a meningococcal conjugate vaccine that stimulates the immune system to produce antibodies against serogroups A, C, W, and Y of Neisseria meningitidis.
Placebo for Inhalation
A placebo inhalation formulation that contains no active pharmaceutical ingredient and serves as a control comparator in clinical trials.
TT · Immunology / Infectious Disease
TT is a recombinant adenovirus type 5 vector-based vaccine that expresses the SARS-CoV-2 spike protein to elicit immune responses against COVID-19.

Phase 3 pipeline

batch 2 of MCV4 · Infectious Disease
MCV4 is a vaccine that stimulates the body's immune response to the meningococcal conjugate serogroups A, C, W, and Y.
batch 3 of MCV4 · Infectious Diseases
MCV4 is a vaccine that stimulates the body's immune response to the meningococcal conjugate serogroups A, C, W, and Y.
DTcP · Immunology
DTcP is a recombinant protein subunit vaccine that stimulates immune responses against diphtheria, tetanus, and pertussis antigens.
MPSV4 · Immunology / Infectious Disease
MPSV4 is a meningococcal polysaccharide conjugate vaccine that stimulates immune responses against multiple serogroups of Neisseria meningitidis.
mRNA vaccine BNT162b2 (Pfizer) · Immunology / Infectious Disease
BNT162b2 is an mRNA vaccine that instructs cells to produce the SARS-CoV-2 spike protein, triggering an immune response to prevent COVID-19 infection.
MSPV4 · Immunology / Infectious Disease
MSPV4 is a recombinant meningococcal serogroup B, C, W, and Y conjugate vaccine that stimulates immune responses against multiple meningococcal serogroups.
PCV13i · Infectious disease
PCV13i is a conjugate vaccine that stimulates the body's immune response to protect against invasive pneumococcal disease caused by Streptococcus pneumoniae serotypes 1, 3, 5, 6A, 6B, 7F, 8, 9V, 19A, 19F, and 22F.
TTVA · Infectious Disease
TTVA is a vaccine that induces an immune response against the SARS-CoV-2 virus.

Phase 2 pipeline

Tdcp

Phase 1 pipeline

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: